Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

NEOGENOMICS LABORATORIES — Lobbying — Receipts Report

LD-2 disclosure · 4th Quarter - Termination

NEOGENOMICS LABORATORIES

via MR. ALAN MERTZ

4th Quarter (Oct 1 - Dec 31) · 2021Posted Feb 18, 2022Filing document ↗LDA record ↗

Income$50Kfee reported

Client

Name: NEOGENOMICS LABORATORIES
Description: Oncology diagnostic testing company
Location: Florida · United States of America

Registrant

Firm: MR. ALAN MERTZ
Description: Consulting LLC
Location: Naples, Florida, United States of America

Lobbying activities

1 issue

Health Issues
VALID legislation on genetic testing
LobbyistsALAN MERTZ
TargetedHealth & Human Services, Dept of (HHS)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.